id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S5175 R13493 |
Liu (Controls exposed to LDT), 2019 | 1 min Apgar Score < 10 | 3rd trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Control group: telbivudine Exposed group: TDF (only) Indication: CHB |
0.98 [0.38;2.52] C excluded (control group) |
8/325 10/400 | 18 | 325 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5174 R13486 |
Liu (Controls unexposed, sick), 2019 | 1 min Apgar Score < 10 | 3rd trimester | prospective cohort | unexposed, sick | Adjustment: No Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB | 3.41 [0.42;27.51] C | 8/325 1/136 | 9 | 325 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5304 R13747 |
Jourdain a, 2018 | Apgar score < 7 (at 1 min) | 3rd trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB | 0.65 [0.11;3.92] C | 2/163 3/159 | 5 | 163 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5321 R13799 |
Lin, 2018 | Low Apgar scores (<7) at 1 min | 3rd trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB | 1.85 [0.16;21.08] C | 2/57 1/52 | 3 | 57 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5244 R13563 |
Greenup (Controls exposed to lamivudine), 2014 | Abnormal APGAR < 8 (1min) | 2nd and/or 3rd trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Control group: Lamivudine Exposed group: TDF (only) Indication: CHB |
0.36 [0.10;1.26] C excluded (control group) |
4/58 9/53 | 13 | 58 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5243 R13553 |
Greenup (Controls unexposed, sick), 2014 | Abnormal APGAR < 8 (1min) | 2nd and/or 3rd trimester | prospective cohort | unexposed, sick | Adjustment: No Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB | 1.41 [0.15;13.39] C | 4/58 1/20 | 5 | 58 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.42 [0.50;4.07] | 22 | 603 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 5244, 5175